# dMed Biopharmaceutical Co.

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/dmed-biopharmaceutical-co

- Industry: Pharmaceuticals
- Headquarters: Shanghai, China
- Website: www.caidya.cn
- Total disclosed funding: $214M
- Latest round: Series C (Jul 7, 2021)
- Investors on record: 13

## About

Founded in 2016 and based in Shanghai, China, dMed Biopharmaceutical Co., Ltd. operates as a clinical contract research organization that provides drug services and solutions to improve and accelerate clinical and drug development. It has branch offices in New York and Eschborn. The chairman of the board, Lingshi Tan, graduated from University of Pittsburgh and is a chairman of the Drug Information Association Board of Directors. The company has cooperated with ClinsChain, Eurofins, KingMed Diagnostics and other enteprises. In October, it changed its name from dMed to Caidya. In January 2025, Caidya raised USD 165 million in strategic investment from new investor Rubicon Founders.

The company mainly provides new drug R&D contract outsourcing services, providing users with clinical trial design, data management and system development, clinical development and registration strategy services. The company's services can be used in oncology, hematology, rare diseases, pediatric diseases and other disciplines.

The company generates revenue by providing new drug R&D contract outsourcing services including early clinical development, clinical trial operations, data management, and drug safety.

## Funding rounds

- Series C, Jul 7, 2021, $50M — Hong Shan, Vivo Capital, Qiming Venture Partners, Lilly Asia Ventures, Fidelity Investments, Kaiser Permanente Ventures, Rock Springs Capital, E Fund Management Co.,Ltd, Superstring Capital Management, Springhill Fund Asset Management (HK) Company
- Series C, Dec 17, 2020, $100M — Hong Shan, Vivo Capital, Qiming Venture Partners, Lilly Asia Ventures, Fidelity Investments, Kaiser Permanente Ventures, E Fund Management Co.,Ltd
- Series B, Oct 16, 2019, $50M — Legend Capital, Vivo Capital, Qiming Venture Partners, Lilly Asia Ventures
- Series B, Jul 1, 2018, $6M — Qiming Venture Partners
- Series A, Nov 30, 2016, $8M — Qiming Venture Partners, ZAI Lab Limited, Tigermed

## Investors

- Qiming Venture Partners (https://capitalatlas.ai/funds/qiming-venture-partners) — Series A, Series B, Series C
- ZAI Lab Limited — Series A
- Tigermed (https://capitalatlas.ai/funds/tigermed) — Series A
- Legend Capital — Series B
- Vivo Capital (https://capitalatlas.ai/funds/vivo-capital) — Series B, Series C
- Lilly Asia Ventures (https://capitalatlas.ai/funds/lilly-asia-ventures) — Series B, Series C
- Hong Shan — Series C
- Fidelity Investments (https://capitalatlas.ai/funds/fidelity-investments) — Series C
- Kaiser Permanente Ventures (https://capitalatlas.ai/funds/kaiser-permanente-ventures) — Series C
- E Fund Management Co.,Ltd — Series C
- Rock Springs Capital — Series C
- Superstring Capital Management (https://capitalatlas.ai/funds/superstring-capital-management) — Series C
- Springhill Fund Asset Management (HK) Company — Series C